Company Renalytix Plc Nasdaq

Equities

RNLX

US75973T1016

Advanced Medical Equipment & Technology

Delayed Nasdaq 07:08:03 14/05/2024 pm IST 5-day change 1st Jan Change
0.6496 USD +4.93% Intraday chart for Renalytix Plc -6.00% +66.56%

Business Summary

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Number of employees: 102

Sales per Business

GBP in Million2022Weight2023Weight Delta
Artificial Intelligence-enabled in Vitro Diagnostics
100.0 %
2 100.0 % 3 100.0 % +26.61%

Sales per region

GBP in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
2 100.0 % 3 100.0 % +26.61%

Managers

Managers TitleAgeSince
Founder 56 15/18/15
Director of Finance/CFO 54 15/18/15
President 63 01/23/01
Chief Tech/Sci/R&D Officer 57 15/18/15
Chief Tech/Sci/R&D Officer 70 15/18/15
Corporate Officer/Principal - 22/21/22
Sales & Marketing - 07/21/07
Corporate Secretary - -
Sales & Marketing 64 07/21/07

Members of the board

Members of the board TitleAgeSince
Director/Board Member 73 30/21/30
Chairman 72 15/18/15
Founder 56 15/18/15
Chief Tech/Sci/R&D Officer 57 15/18/15
Director/Board Member 56 01/18/01
Director/Board Member 58 30/23/30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 154,368,191 99,307,151 ( 64.33 %) 0 64.33 %

Shareholders

NameEquities%Valuation
The Mount Sinai Hospital
18.80 %
23,979,726 18.80 % 6 M $
Polar Capital LLP
10.87 %
13,866,061 10.87 % 4 M $
10,072,500 7.897 % 3 M $
Jefferson River Capital LLC
6.690 %
8,533,280 6.690 % 2 M $
Susquehanna Investment Group LLC
6.165 %
7,863,212 6.165 % 2 M $
Heights Capital Management, Inc.
5.099 %
6,503,384 5.099 % 2 M $
Pentwater Capital Management LP
4.536 %
5,785,196 4.536 % 2 M $
5,743,476 4.503 % 2 M $
Lombard Odier Asset Management (Europe) Ltd.
3.136 %
4,000,000 3.136 % 1 M $
Harwood Capital LLP
2.195 %
2,800,000 2.195 % 753 788 $
NameEquities%Valuation
Jefferson River Capital LLC
6.690 %
4,266,640 6.690 % 3 M $
Pentwater Capital Management LP
1.976 %
1,260,000 1.976 % 786 240 $
Gilder, Gagnon, Howe & Co. LLC
1.379 %
879,451 1.379 % 548 777 $
Pentwater Capital Management LP
1.098 %
700,000 1.098 % 436 800 $
Pinnacle Associates Ltd.
1.091 %
696,005 1.091 % 434 307 $
Tejara Capital Ltd.
0.6278 %
400,394 0.6278 % 249 846 $
Corient Private Wealth LLC
0.5261 %
335,514 0.5261 % 209 361 $
Gofen & Glossberg LLC
0.2951 %
188,224 0.2951 % 117 452 $
Lazard Asset Management LLC
0.2142 %
136,620 0.2142 % 85 251 $
Citadel Securities GP LLC
0.1637 %
104,392 0.1637 % 65 141 $

Company contact information

Renalytix Plc

1460 Broadway

10036, New York

+646 397 3970

http://www.renalytixai.com
address Renalytix Plc(RNLX)
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW